Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 267 adults with moderate to severe psoriasis across six groups. Forty-five participants received a placebo (a dummy treatment with no active ingredient), while the remaining participants received different doses and schedules of an investigational medicine called BMS-986165 (now known as deucravacitinib). The trial ran for 12 weeks and was primarily measuring how many participants in each group saw their psoriasis severity score — called a PASI score, which rates the extent and seriousness of skin plaques — drop by at least 75% from where it started. The reported data shows that by week 12, around 6.7% of participants in the placebo group reached that 75% improvement mark. In comparison, the figures reported for the BMS-986165 groups ranged from 9.1% (at the lowest dose, taken every other day) up to 75.0% (at the highest once-daily dose). For the secondary measures, the reported data shows that a higher proportion of participants in the higher-dose groups also reached 50%, 90%, and 100% improvement thresholds compared with the placebo group. A doctor's overall skin clearance rating of "clear" or "almost clear" was reported in 6.7% of the placebo group, compared with between 20.5% and 75.6% across the BMS-986165 groups. Participants' self-reported quality-of-life scores and the percentage of body surface area affected by psoriasis also showed greater reductions from baseline in higher-dose groups compared with placebo, based on the reported figures. A PASI-100 result (complete clearance) was not separately reported in the data provided for that secondary outcome, so those figures are not available here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 39283417) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Psoriasis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 70 years old (male or female)
- You have been diagnosed with plaque psoriasis for at least 6 months
- If you are a woman who could become pregnant, you must have a negative pregnancy test and must not currently be pregnant, breastfeeding, or planning to become pregnant
- If you are a man who is sexually active with a woman who could become pregnant, you must agree to use contraception during the treatment period and for a set time afterward
Who may not be able to join:
- You have a significant ongoing or serious medical condition
- You have had a blood transfusion within the last 4 weeks
- You are unable to swallow or take oral (by mouth) medication
- You have tested positive for Hepatitis B
- You have tested positive for Hepatitis C
- You have a history of or are at risk for tuberculosis (TB)
- You have a major illness or an unstable health condition
- A chest X-ray taken at screening shows signs of possible infection
- You have received the psoriasis medications ustekinumab, secukinumab, or ixekizumab within the last 6 months
- You have received anti-TNF medications (a type of immune-suppressing treatment) within the last 2 months
- You have received a medication called Rituximab within the last 6 months
- You have used any topical (applied to the skin) psoriasis treatments within the last 2 weeks
- You have taken any systemic (whole-body) psoriasis medications within the last 4 weeks
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Day 85 (Week 12); Number of Participants With Adverse Events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.